Genomic Health, Inc.
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. The company's first commercial product is Oncotype DX, a diagnostic multigene expression test service that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of patient survival within 10 years of diagnosis and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 2600 breast cancer patients, including rigorous validation studies. Genomic Health's goal is to build similar tests that can prove useful across a range of cancer types.